关键词: Celgene 氘修饰药物
2013年5月7日讯 /生物谷BIOON/ --赛尔基因(Celgene)昨日宣布,与Concert制药达成了氘化药物(Deuterium Drug)开发合作。
根据协议,Celgene将利用Concert制药的氘化化学实体(deuterated chemical entity,DCE)平台,创造新的氘修饰(deuterium-modified )小分子化合物,靶向癌症和炎症靶标。
Celgene已同意支付一笔预付款。此外,若Celgene同意进一步开发基于DCE的药物,Concert制药将有资格从每一个开发项目中收获总额超过3亿美元的开发、监管、销售里程碑款项,以及每一个项目所开发药物在未来销售的分层特许权使用费。
氘(deuterium)是氢(hydrogen)的同位素,原子质量是后者的2倍,与碳(carbon)的结合更强。
Concert制药成立于2006年,目标是将其DCE技术应用于已获批的药物及已知人类药理活性的制剂,来创造疗效更强、耐受性更好、安全性更高的新药物。
Concert制药开发管线包含针对各种疾病的化合物,其中走的最远的是CTP-499,该药是糖尿病肾脏疾病的候选药物,目前处于II期临床开发。(生物谷bioon.com)
英文原文:
Celgene, Concert in $300M+ Deuterium Drug Collaboration
Celgene will use Concert Pharmaceuticals’ deuterated chemical entity (DCE) Platform? technology to create new deuterium-modified small molecule compounds targeting cancer and inflammation, in a collaboration that could net the latter more than $300 million.
In return for using the DCE technology, Celgene agreed to give Concert an up-front payment. And if Celgene exercises its options and agrees to develop DCE-based drugs, Concert will be eligible for more than $300 million in payments tied to development, regulatory, and sales milestones for each program selected for development by Celgene. In addition, Concert will receive tiered royalties on any product sales for each of the programs advanced by Celgene.
Founded in 2006, Concert seeks to apply its DCE technology to approved drugs and other agents with known human pharmacological activity, with the goal of creating new medicines that the company says have potential for enhanced efficacy, better tolerability and improved safety. Deuterium is an isotope of hydrogen with twice its atomic mass, allowing for stronger bonding with carbon, yet according to the company it has yet to be systematically studied for its safety and efficacy in medicines.
“Celgene’s deep experience developing clinically meaningful therapies, and their global commitment to patients across multiple therapeutic areas, make them an ideal partner,” Roger Tung, Ph.D., Concert’s president and CEO, said in a statement. “We look forward to working with Celgene to evaluate the potential benefits of deuterium-modification for a number of programs emerging in our pipeline.”
Concert’s pipeline includes compounds for a variety of disorders. Furthest along is CTP-499, a diabetic kidney disease drug candidate now in Phase II development.
Next furthest along in the pipeline is AVP-786, a Phase I neurologic disorders drug candidate being developed with Avanir Pharmaceuticals under an undisclosed but reportedly $200 million-plus collaboration announced last year. Also in Concert’s pipeline are CTP-3534 for spasticity and neuropathic pain; C-10068 for epilepsy and depression; D-Ivacaftor for cystic fibrosis and COPD; and D-Praziquantel, now in a research phase for schistosomiasis.
The collaborations with Avanir and now Celgene mark two of three partnerships Concert has entered into in the past 15 months. The other collaboration, announced February 26, combines Concert with Jazz Pharmaceuticals in the development of narcolepsy drug C-10323, now in a preclinical phase, also for an undisclosed sum but including what several news accounts reported as $120 million in milestone and royalty payments.
(责任编辑:jie.jiang)